Semaglutide vs Dulaglutide on Epicardial Adipose Tissue

Epicardial Fat Clinical Trial

Official title: Effects of Semaglutide vs Dulaglutide on Epicardial Adipose Tissue Thickness in Subjects With Type 2 Diabetes and Obesity

Status Completed

Clinical Trial Summary

Epicardial Fat (EAT), the visceral fat depot of the heart, is a modifiable cardio-metabolic risk factor and therapeutic target. EAT expresses GLP-1 receptors (GLP-1R). GLP-1 receptor agonist liraglutide is known to significantly decrease EAT thickness. However, the effects of GLP-1 receptor agonists semaglutide and dulaglutide on EAT thickness are unknown

Clinical Trial Description

This is a retrospective, observational, case control study. Data were obtained from retrospective review of the electronic medical records. Patients were treated with either semaglutide, dulaglutide or metformin as standard of care, during routine clinical practice, regardless of the study. Each patient underwent routine labs and an onsite ultrasound measurement of EAT thickness at baseline and at the routine 12-week follow up visit, as standard of care. ;

Related Conditions & MeSH terms

• Epicardial Fat

• NCT number: NCT04200625
• Study type: Observational
• Source: University of Miami
• Status: Completed
• Start date: September 24, 2019
• Completion date: December 9, 2019